Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ NEWS2 score 77% Improvement Relative Risk Oxygen therapy 92% Oxygen time 70% Hospitalization time 13% Viral clearance 10% Hellou et al. NCT04382040 Vitamin C RCT LATE TREATMENT Is late treatment with vitamin C+combined treatments beneficial for COVID-19? Double-blind RCT 50 patients in Israel Improved recovery (p=0.042) and lower need for oxygen therapy (p=0.01) Hellou et al., J. Cellular and Molecular Medicine, doi:10.1111/jcmm.17337 Favors vitamin C Favors control
Effect of ArtemiC in patients with COVID-19: A Phase II prospective study
Hellou et al., Journal of Cellular and Molecular Medicine, doi:10.1111/jcmm.17337, NCT04382040 (history)
Hellou et al., Effect of ArtemiC in patients with COVID-19: A Phase II prospective study, Journal of Cellular and Molecular Medicine, doi:10.1111/jcmm.17337, NCT04382040
May 2022   Source   PDF  
  All Studies   Meta
RCT 50 hospitalized patients in Israel, 33 treated with curcumin, vitamin C, artemisinin, and frankincense oral spray, showing improved recovery with treatment. This study is excluded in meta analysis: combined treatments may contribute more to the effect seen.
relative NEWS2 score, 76.7% better, RR 0.23, p = 0.04, treatment mean 0.52 (±0.67) n=33, control mean 2.23 (±3.2) n=17, day 15.
risk of oxygen therapy, 92.2% lower, RR 0.08, p = 0.01, treatment 0 of 33 (0.0%), control 4 of 17 (23.5%), NNT 4.2, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 15.
oxygen time, 69.7% lower, relative time 0.30, p = 0.17, treatment mean 2.3 (±1.4) n=33, control mean 7.6 (±4.6) n=17.
hospitalization time, 13.3% lower, relative time 0.87, p = 0.92, treatment mean 7.8 (±7.3) n=33, control mean 9.0 (±8.0) n=17.
risk of no viral clearance, 9.8% lower, RR 0.90, p = 0.77, treatment 14 of 33 (42.4%), control 8 of 17 (47.1%), NNT 22, day 15.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hellou et al., 19 May 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Israel, peer-reviewed, 6 authors, this trial uses multiple treatments in the treatment arm (combined with curcumin, artemisinin, and frankincense) - results of individual treatments may vary, trial NCT04382040 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin CAll
Abstract: Received: 12 September 2021 | Revised: 6 March 2022 | Accepted: 5 April 2022 DOI: 10.1111/jcmm.17337 ORIGINAL ARTICLE Effect of ArtemiC in patients with COVID-­19: A Phase II prospective study Elias Hellou1,2,3 | Jameel Mohsin2,3 | Ameer Elemy4 | Fahed Hakim4,5 | Mona Mustafa-­Hellou3,6 | Shadi Hamoud3,6 1 Department of Cardiology, E.M.M.S Hospital, Nazareth, Israel 2 Department of Cardiology, Hillel Yaffe Hospital, Hadera, Israel 3 Rappaport Faculty of Medicine, Technion-­Israel Institute of Technology, Haifa, Israel 4 Victory Department for COVID-­19 Patients, E.M.M.S Hospital, Nazareth, Israel 5 Azrieli Faculty of Medicine, Bar-­Ilan University, Zefat, Israel 6 Department of Internal Medicine E, Rambam Health Care Campus, Haifa, Israel Correspondence Elias Hellou, Department of Cardiology, E.M.M.S Hospital, POB 201, Nazareth ZIP 16000, Israel. Email: Abstract Despite intensive efforts, there is no effective remedy for COVID-­19. Moreover, vaccination efficacy declines over time and may be compromised against new SARS-­CoV-­2 lineages. Therefore, there remains an unmet need for simple, accessible, low-­cost and effective pharmacological anti-­SARS-­CoV-­2 agents. ArtemiC is a medical product comprising artemisinin, curcumin, frankincense and vitamin C, all of which possess anti-­inflammatory and anti-­oxidant properties. The present Phase II placebo-­controlled, double-­blinded, multi-­centred, prospective study evaluated the efficacy and safety of ArtemiC in patients with COVID-­19. The study included 50 hospitalized symptomatic COVID-­19 patients randomized (2:1) to receive ArtemiC or placebo oral spray, twice daily on Days 1 and 2, beside standard care. A physical examination was performed, and vital signs and blood tests were monitored daily until hospital discharge (or Day 15). A PCR assessment of SARS-­CoV-­2 carriage was performed at screening and on last visit. ArtemiC improved NEWS2 in 91% of patients and shortened durations of abnormal SpO2 levels, oxygen supplementation and fever. No treatment-­related adverse events were reported. These findings suggest that ArtemiC curbed deterioration, possibly by limiting cytokine storm of COVID-­19, thus bearing great promise for COVID-­19 patients, particularly those with comorbidities. KEYWORDS ArtemiC, artemisinin, COVID-­19, curcumin, Vitamin C 1 | I NTRO D U C TI O N organs, particularly in aged patients with diabetes, obesity, hypertension, heart failure and respiratory diseases. 2,3 Critically ill cases The coronavirus disease 2019 (COVID-­19) pandemic, which initially are characterized by acute respiratory distress syndrome (ARDS) emerged in Wuhan-­South-­eastern China in 2019, is caused by severe and septic shock, as well as multiple organ dysfunction or failure. 2–­4 acute respiratory syndrome coronavirus 2 (SARS-­CoV-­2) and is as- Human angiotensin-­converting enzyme 2 (ACE2) receptor serves as sociated with significant morbidity and mortality among vulnerable the binding domain of SARS-­CoV-­2 in human host cells, exploiting patients.1 This grim situation is mainly attributed to the poor under- its high affinity to this enzyme to inflict remarkable damage to key standing of the pathogenesis of SARS-­CoV-­2-­induced injury to vital target organs.5–­7 This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop